This prompted us to investigate a double β-catenin/NHERF1-inhibitory strategy as a fruitful approach to augment apoptotic death of CRC cells refractory to Wnt-targeted agents, indicating RS5517 as a novel NHERF1/PDZ1-domain ligand antagonist with a promising therapeutic value. Here, NHERF1 is linked to colorectal carcinoma.